{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:08:42Z","timestamp":1779224922657,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although therapeutic drug monitoring of calcineurin inhibitor (CNI) concentrations is performed routinely in clinical practice, an identical concentration may lead to different effects in different patients. Although the quantification of nuclear factor of activated T-cell\u2013regulated gene expression (NFAT-RGE) is a promising method for measuring individual CNI effects, CNI pharmacodynamics are as of yet incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>CNI concentrations and NFAT-RGEs were quantified in 24 healthy volunteers receiving either ciclosporin or tacrolimus in 2 clinical trials. NFAT-RGE was measured using quantitative reverse transcription polymerase chain reaction tests of whole-blood samples. Pharmacokinetics and pharmacodynamics were analyzed using compartmental modeling and simulation. In addition, NFAT-RGE data from renal transplant patients were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The average NFAT-RGE during a dose interval was reduced to approximately 50% with ciclosporin, considering circadian changes. The different effect\u2013time course with ciclosporin and tacrolimus could be explained by differences in potency (IC\n                      <jats:sub>50<\/jats:sub>\n                      204 \u00b1 41 versus 15.1 \u00b1 3.2 mcg\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and pharmacokinetics. Residual NFAT-RGE at the time of maximum concentration (RGE\n                      <jats:sub>tmax<\/jats:sub>\n                      ) of 15% when using ciclosporin and of 30% when using tacrolimus was associated with similar average NFAT-RGEs during a dose interval. Renal transplant patients had similar but slightly stronger effects compared with healthy volunteers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Ciclosporin and tacrolimus led to similar average suppression of NFAT-RGE in a dose interval, despite considerably different RGE\n                      <jats:sub>tmax<\/jats:sub>\n                      . Pharmacodynamic monitoring of average NFAT-RGE should be considered. When using NFAT-RGE at specific time points, the different effect\u2013time courses and circadian changes of NFAT-RGEs should be considered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001046","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T17:00:06Z","timestamp":1664816406000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacodynamic Monitoring of Ciclosporin and Tacrolimus: Insights From Nuclear Factor of Activated T-Cell\u2013Regulated Gene Expression in Healthy Volunteers"],"prefix":"10.1097","volume":"45","author":[{"given":"Yoana Aurelia","family":"Djaelani","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"German Center for Infection Research (DZIF), Partner Site Heidelberg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Giese","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Heidelberg;"},{"name":"Nephrology, University Hospital Heidelberg, Heidelberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"German Center for Infection Research (DZIF), Partner Site Heidelberg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"German Center for Infection Research (DZIF), Partner Site Heidelberg;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"Jonge","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00228-018-2546-x","article-title":"FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients","volume":"75","author":"Wu","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/pgs-2016-0171","article-title":"NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients","volume":"18","author":"Xu","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"suppl 1","key":"R6-20260519","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/FTD.0000000000000234","article-title":"Nuclear factor of activated T cells-regulated gene expression as predictive biomarker of personal response to calcineurin inhibitors","volume":"38","author":"Sommerer","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/TP.0000000000001973","article-title":"Improved pulse wave velocity and renal function in individualized calcineurin inhibitor treatment by immunomonitoring: the randomized controlled calcineurin inhibitor-sparing trial","volume":"102","author":"Sommerer","year":"2018","journal-title":"Transplantation"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.TP.0000109260.00094.01","article-title":"Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A","volume":"77","author":"Giese","year":"2004","journal-title":"Transplantation"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/01.tp.0000243358.75863.57","article-title":"Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies","volume":"82","author":"Sommerer","year":"2006","journal-title":"Transplantation"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FTD.0000000000000340","article-title":"Analytical validation and cross-validation of an NFAT-regulated gene expression assay for pharmacodynamic monitoring of therapy with calcineurin inhibitors","volume":"38","author":"Abdel-Kahaar","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/bcp.13367","article-title":"NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation","volume":"83","author":"Bremer","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/TP.0b013e3181dc13b6","article-title":"Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients","volume":"89","author":"Sommerer","year":"2010","journal-title":"Transplantation"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FTD.0b013e318226dac7","article-title":"Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia","volume":"33","author":"Sommerer","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"32","DOI":"10.12659\/AOT.889809","article-title":"Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study","volume":"19","author":"Zahn","year":"2014","journal-title":"Ann Transpl"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5414\/CN108623","article-title":"Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A","volume":"84","author":"Sommerer","year":"2015","journal-title":"Clin Nephrol"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1111\/bcp.14794","article-title":"Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: results of the IMAGEN study","volume":"87","author":"Sommerer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1432-2277.2007.00552.x","article-title":"Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients","volume":"20","author":"Konstandin","year":"2007","journal-title":"Transpl Int"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/tid.12206","article-title":"Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation","volume":"16","author":"Steinebrunner","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1399-0012.2008.00819.x","article-title":"Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients","volume":"22","author":"Sommerer","year":"2008","journal-title":"Clin Transplant"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-051X.2011.01773.x","article-title":"Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study","volume":"38","author":"Dannewitz","year":"2011","journal-title":"J Clin Periodontol"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/TXD.0000000000000810","article-title":"Nuclear factor of activated T cell-regulated cytokine gene expression for adjustment of tacrolimus in kidney transplant recipients: A randomized controlled pilot trial","volume":"4","author":"Webber","year":"2018","journal-title":"Transplant Direct"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/lt.22254","article-title":"Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients","volume":"17","author":"Zahn","year":"2011","journal-title":"Liver Transpl"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/TP.0b013e318199c1c7","article-title":"Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation","volume":"87","author":"Opelz","year":"2009","journal-title":"Transplantation"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/lt.23925","article-title":"Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy","volume":"20","author":"Roos","year":"2014","journal-title":"Liver Transpl"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI118159","article-title":"Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible","volume":"96","author":"Batiuk","year":"1995","journal-title":"J Clin Invest"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/00007890-199911150-00023","article-title":"The temporal profile of calcineurin inhibition by cyclosporine in vivo","volume":"68","author":"Halloran","year":"1999","journal-title":"Transplantation"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers","volume":"85","author":"Brings","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R29-20260519","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cpt.1529","article-title":"Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor voriconazole in healthy volunteers","volume":"106","author":"Huppertz","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/00003088-200645090-00003","article-title":"Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients","volume":"45","author":"Saint-Marcoux","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","article-title":"Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients","volume":"48","author":"Benkali","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/j.1552-4604.1996.tb04761.x","article-title":"Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate","volume":"36","author":"Rohatagi","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy","volume":"24","author":"Griny\u00f3","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","article-title":"The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation","volume":"64","author":"Hale","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cpt.2220","article-title":"Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients","volume":"110","author":"Fontova","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:00:21Z","timestamp":1779224421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001046","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2022-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}